Being diagnosed with IgA nephropathy—also known as Berger’s disease—can raise immediate concerns about kidney function, long-term stability, and how to protect your family financially. One of the most common questions we hear is whether life insurance is still available, whether it will be affordable, and whether the diagnosis automatically triggers a decline.

The good news is that many people with IgA nephropathy can still qualify for life insurance. Underwriting outcomes are driven far more by measurable kidney health than by the diagnosis name alone. When lab trends are stable, blood pressure is controlled, and proteinuria is low or improving, fully underwritten term or permanent life insurance can be realistic. When the disease is more advanced or labs show declining function, coverage may still be possible—often with higher ratings or with coverage structured differently.

At Diversified Insurance Brokers, we take a case-by-case underwriting approach for kidney conditions. Instead of relying on one insurer’s appetite, our advisors match your profile with carriers that evaluate renal histories more reasonably and that focus on objective metrics—like eGFR trends and treatment stability—rather than blanket assumptions. For a broader overview of medically underwritten policies, start with our guide on life insurance with pre-existing conditions.

What Is IgA Nephropathy?

IgA nephropathy is an immune-mediated kidney disorder where immunoglobulin A (IgA) deposits build up in the kidney’s filtering units (glomeruli). Over time, that inflammation can interfere with filtration and, in some cases, contribute to chronic kidney disease (CKD). The key point is that progression varies widely. Some people remain stable for decades with minimal loss of function, while others develop higher proteinuria, worsening blood pressure, and declining eGFR.

From a life insurance underwriting perspective, this is why the diagnosis alone doesn’t determine insurability. Underwriters are primarily evaluating whether your kidneys are functioning well today, how stable the trend has been over time, and whether there are signs of accelerating progression or complications.

How Life Insurance Underwriters Evaluate IgA Nephropathy

For IgA nephropathy, carriers focus on objective data. The strongest applications tell a clear “trend story” that an underwriter can verify quickly. In most cases, that means stable labs over time, controlled blood pressure, and documentation that the condition is being followed appropriately by a nephrologist.

Kidney function and trend: Underwriters look at creatinine and—most importantly—your estimated glomerular filtration rate (eGFR). A single eGFR reading matters, but the direction matters more. Stable results across multiple years can significantly improve outcomes versus a file with a downward trend.

Proteinuria / albumin: Protein in the urine is a major risk marker in IgA nephropathy. Carriers will often request the most recent urine microalbumin or protein results, and they may compare that to prior years. Lower levels—or levels that have improved with treatment—are typically viewed more favorably.

Blood pressure management: Hypertension can accelerate kidney decline, so insurers pay close attention to BP control and medication compliance. Many applicants with renal conditions are treated with ACE inhibitors or ARBs, and underwriters generally like seeing a consistent, well-managed regimen. If you’re dealing with elevated readings, our page on life insurance for high blood pressure explains how control and stability influence rate class.

Complications and comorbidities: Underwriters also look for related risks that can change the overall profile—such as diabetes markers, cardiovascular disease, or evidence of advanced CKD. If complications are present, the case becomes about the full health picture, not just IgA nephropathy.

Specialist follow-up: Consistent nephrology care, clear treatment notes, and documented stability can reduce carrier hesitation. If records show gaps in follow-up or uncertainty about progression, carriers tend to be more conservative.

If you want context on how carriers gather labs during underwriting, see what to expect during a life insurance exam.

What Often Leads to Better Rate Classes

Most people with IgA nephropathy don’t need a “perfect” file to qualify, but there are a few consistent factors that tend to improve approvals and pricing. Underwriters generally respond best when the case shows predictable stability rather than uncertainty.

First, stable or improving lab trends tend to move outcomes in the right direction—especially stable eGFR and lower proteinuria. Second, controlled blood pressure and a consistent medication routine show that risk is being managed proactively. Third, applicants who are non-smokers with a healthier build and no major related conditions often see better offers than applicants where multiple risk factors stack together.

Because carriers vary widely in how aggressively they “stack” risk, the broker strategy matters. One insurer may heavily penalize a moderate A1C or elevated BP alongside kidney impairment, while another carrier may price the same profile more reasonably when the kidney trend is stable. This is why we typically pre-screen IgA nephropathy cases before choosing where to submit.

Life Insurance Options for IgA Nephropathy

Many applicants with IgA nephropathy are eligible for fully underwritten term life insurance, especially when kidney function is stable and complications are not present. Preferred categories can be harder to reach with renal histories, but standard or table-rated approvals are common when labs are supportive. Term coverage is often the most cost-effective way to protect income, family obligations, and time-bound needs.

Permanent life insurance may also be available for stable cases, depending on age, kidney metrics, and the rest of your profile. Permanent coverage can be a fit when long-term needs are the priority, such as estate planning, lifelong dependents, or final expense planning. Underwriting for permanent policies still relies on the same kidney metrics—so the stability story remains central.

When kidney impairment is more advanced—or the case includes multiple compounding risks—coverage may still be possible but structured differently. In those situations, we may consider simplified-issue options for smaller face amounts or use coverage layering (for example, combining a smaller simplified-issue policy with a larger underwritten policy when the case supports it). If your options are limited, we’ll also discuss whether a smaller policy designed for final expenses makes sense and how it compares to other routes.

Why a Kidney-Specific Underwriting Review Matters

Kidney cases are not an area where “submit and hope” works well. Carriers differ dramatically in how they treat IgA nephropathy. Some insurers take an overly conservative stance by default, while others take a more data-driven approach when trends are stable. Submitting to the wrong carrier first can lead to a decline that complicates future submissions—especially if the decline triggers more scrutiny or additional requirements.

That’s why we use a kidney-specific review strategy. A targeted questionnaire helps clarify the details that actually drive underwriting: current eGFR, how long the trend has been stable, presence and level of proteinuria, blood pressure control, medication regimen, any biopsy confirmation or specialist notes, and whether there’s been progression toward later-stage CKD. When the file is packaged correctly, carriers can make a cleaner decision with fewer delays.

This approach protects insurability, reduces wasted time, and helps ensure you’re presented to the most appropriate insurers from the start—rather than letting the first carrier define your outcome.

Why Diversified Insurance Brokers Is Different

Diversified Insurance Brokers is a family-owned, independent insurance agency that has helped clients with complex medical histories secure coverage since 1980. With access to dozens of highly rated carriers nationwide, cases involving kidney disease are matched with insurers known for more flexible underwriting when lab trends support it. Our advisors focus on protecting insurability, minimizing preventable declines, and identifying the strongest offer available based on the complete medical picture—not assumptions.

If you’d like to learn more about how we structure life insurance cases and compare carriers, visit our main life insurance services page.